7.00

2.12% 0.17

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $7.00, with a volume of 1.24M. It is up +2.12% in the last 24 hours and down -49.64% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$6.83

Open:

$6.638

24h Volume:

1.24M

Relative Volume:

0.29

Market Cap:

$1.32B

Revenue:

$42.73M

Net Income/Loss:

$-204.38M

P/E Ratio:

-5.7737

EPS:

-1.2124

Net Cash Flow:

$-189.73M

1W Performance:

+12.49%

1M Performance:

-49.64%

6M Performance:

-0.65%

1Y Performance:

-7.87%

1-Day Range:

$6.61

$7.08

1-Week Range:

$6.00

$7.80

52-Week Range:

$5.02

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

317

Twitter

@WAVELifeSci

Next Earnings Date

2025-03-04

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	7.00	1.29B	42.73M	-204.38M	-189.73M	-1.2124
VRTX Vertex Pharmaceuticals Inc	438.76	113.62B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	752.73	82.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.86	46.12B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.55	43.60B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	311.55	34.24B	5.36B	287.73M	924.18M	2.5229

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-26	Initiated	BofA Securities	Buy
Dec-12-25	Reiterated	Wedbush	Outperform
Dec-09-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-04-25	Initiated	Canaccord Genuity	Buy
Jul-28-25	Initiated	Oppenheimer	Outperform
Jul-16-25	Initiated	Citigroup	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

02:56 AM

Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise - NAI500

02:56 AM

Apr 01, 2026

Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains? - qz.com

Apr 01, 2026

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 - Investing News Network

Apr 01, 2026

Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo

Apr 01, 2026

JPMorgan Chase & Co. Has $6.30 Million Position in WAVE Life Sciences Ltd. $WVE - marketbeat.com

Apr 01, 2026

Mar 31, 2026

Wave Life Sciences Stock (WVE) Opinions on INLIGHT Trial Data - Quiver Quantitative

Mar 31, 2026

Mar 30, 2026

[SCHEDULE 13D/A] Wave Life Sciences Ltd. Amended Major Shareholder Report - Stock Titan

Mar 30, 2026

RA Capital boosts Wave Life Sciences (NASDAQ: WVE) stake with 8.8M-share open-market buy - Stock Titan

Mar 30, 2026